Anhedonia

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder

Retrieved on: 
Wednesday, April 3, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Alertness, Depression, EEG, Motivation, ClinicalTrials.gov, MDD, Patient, Neuroscience, Anhedonia, H3, Pleasure, Alto, Cognition, Safety, Pharmacokinetics, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.
  • The present study will evaluate these effects in patients with MDD to determine the potential of ALTO-203 as an antidepressant.
  • “In a Phase 1 study, ALTO-203 demonstrated an acute increase in positive emotion relative to placebo and across several dosage levels.
  • This Phase 2 study consists of two sequential double-blind, placebo-controlled treatment periods and examines two doses of ALTO-203 and placebo given as monotherapy in patients with MDD.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Retrieved on: 
Wednesday, March 13, 2024
Alternative Medicine, Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, JAMA, Depression, Disability, Conference, BTD, Breakthrough therapy, Massachusetts General Hospital, Inc., Psychiatry, Clinical, Grammatical mood, Appetite, MDD, Data analysis, Patient, Knowledge, Disease, Causality, Sleep, Anhedonia, DNB, DSM-IV codes, MBBS, Suicidal ideation, Behavior, Cognition, Event, Hospital, Drug development, Safety, Injury, Multimedia, Plasma protein binding, Sadness, Lancet, BMJ, Pharmaceutical industry

If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

Key Points: 
  • If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.
  • The designation of CYB003 as a breakthrough therapy acknowledges the significant unmet medical need for more effective treatments of MDD and supports CYB003’s potential for significant improvements over existing therapies.
  • With the robust durability data from our Phase 2 study in hand, we are ready to move forward expeditiously.
  • (2022) Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis.

Mindpath Health releases Daddy Issues: Understanding Attachment Trauma

Retrieved on: 
Wednesday, February 21, 2024
DSM, Incidence, Anxiety, Woman, Caregiver, Mental health, Emotion, Love Is Blind, Emotional dysregulation, Friends, Impulsivity, Love, Parent, Life, Risk, Perception, Dysphoria, Fear, Anhedonia, Family, Chronic pain, Hypervigilance, Child, ADHD, Trauma, DSM-IV codes, Doctor of Psychology, Personality disorder, Depression, Nursing

A psychological name for daddy issues: attachment trauma

Key Points: 
  • A psychological name for daddy issues: attachment trauma
    Clearly, 'daddy issues' is not a clinical term, and you won't find it in the DSM.
  • At its core, 'daddy issues' is a label for something very clinical: attachment trauma.
  • Like many forms of trauma, attachment trauma can have real effects on your mental health .
  • Attachment trauma, or the effects of inconsistent or abusive parenting, shows up in several different insecure attachment styles developed by psychologist John Bowlby .

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry

Retrieved on: 
Wednesday, January 31, 2024
Com, Psychosis, Dopamine, Patient, Serotonin, Depression, MDD, Mental health, Phase, Anhedonia, Citalopram, Patent, Prodrug, Pleasure, Pipamperone, Pharmaceutical industry

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry

Key Points: 
  • ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry
    Alken, Belgium – 31 January 2024: ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, today announced the publication of Phase IIIa data for ANT-01, its adjunctive anti-depression drug, in the journal of Personalized Medicine in Psychiatry.
  • The Company also filed a Composition of Matter (CoM) patent for the long-acting effects of ANT-01.
  • The paper was co-authored by Erik Buntinx, Lars Bastiaanse, Alan S Schatzberg, Charles B Nemeroff and Philip D Harvey.
  • At ANeuroTech, we are working to bring effective treatments, with minimal or no side-effects, to patients who suffer with depression.

Pharmactive's Saffron Extract improves Resilience to Occasional Stress

Retrieved on: 
Wednesday, January 24, 2024
DSM-IV codes, Hypothalamus, Arginine, Iterative method, Pituitary gland, Research, Overalls, Manager, Food, Health, Brain-derived neurotrophic factor, HPA, Hormone, Survival, Communication, History, Nutrient, Anxiety, Pandemic, Human, Gland, Doctor of Philosophy, Rat, Anhedonia, ACTH, Adrenocorticotropic hormone, CRF, Brain, Motivation, Glucocorticoid, BDNF, Depression, Growth

MADRID, Jan. 24, 2024 /PRNewswire/ -- A new in vitro study sheds light to the stress relief effect of saffron (Crocus sativus L). The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.

Key Points: 
  • The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.
  • Results demonstrated significant improvements following repeated oral administration of the extract in stress model animal subjects.
  • The HPA axis is a vital brain signaling system involved in orchestrating responses to stress.
  • We are realizing these extend beyond influencing serotonin expression but actually demonstrates a potential to boost resilience to occasional stress and prevent its detrimental impact on overall mental and physical health."

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

Retrieved on: 
Monday, November 27, 2023
Xenon, Șaeș, Physician, Anhedonia, Depression, Epilepsy, American Epilepsy Society, DSM-IV codes, Incidence, SAE, Seizure, Clinical Global Impression, Neurology, Weight gain, MDD, Patient, Safety, Pharmaceutical industry

The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6.

Key Points: 
  • The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6.
  • The mean reduction was 13.90 in the placebo group, 15.61 in the XEN1101 10 mg group and 16.94 in the XEN1101 20 mg group.
  • A clear dose response and a clinically meaningful, but not statistically significant, 3.04 difference between placebo and the XEN1101 20 mg group (p=0.135) was observed.
  • We are excited to share the data generated in X-NOVA with epileptologists and neurologists at the upcoming American Epilepsy Society meeting in December.”

Gedeon Richter: an effective treatment for female schizophrenia patients

Retrieved on: 
Wednesday, October 18, 2023
Cariprazine, Hallucination, Scott Richter, Physician, Asociality, Observational study, Alogia, Patient, ECNP, Gideon, Delusion, Anhedonia, European College of Neuropsychopharmacology, Risperidone, Woman, Pharmaceutical industry, Schizophrenia

Cariprazine was found to be effective in women with schizophrenia in a real-life setting with around 70% of the physicians being satisfied with the results.

Key Points: 
  • Cariprazine was found to be effective in women with schizophrenia in a real-life setting with around 70% of the physicians being satisfied with the results.
  • Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting about 1% of the population.
  • Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
  • Treatment with risperidone is still one of the most used standards when it comes to schizophrenia.

Depression isn't just sadness – it's often a loss of pleasure

Retrieved on: 
Wednesday, August 9, 2023
People, Learning, Hobby, Depression, Life, Schizophrenia, Anxiety, Grammatical mood, Reward, Brain, Research, Dopamine, Science, Functional analytic psychotherapy, Patient, Time, Love, Motivation, Pleasure, Ketamine, Serotonin, Mental health, Pharmaceutical industry, Environmental remediation, Anhedonia

But what many don’t realise is that these aren’t the only symptoms of depression.

Key Points: 
  • But what many don’t realise is that these aren’t the only symptoms of depression.
  • But despite how common this symptom is, it remains one of the most difficult symptoms to treat and manage.

Loss of pleasure

    • Anhedonia is defined as the reduced interest or pleasure in all – or almost all – activities a person previously enjoyed.
    • Although mainly associated with depression, anhedonia can also be a symptom of other disorders – such as schizophrenia, anxiety and Parkinson’s disease.
    • In in-depth interviews my colleagues and I conducted with young people about depression, anhedonia was described by many as not just a loss of joy, but also less motivation to do things.
    • For some, this lack of drive was only related to specific things – such as going to school or seeing friends.
    • But the brain’s reward system isn’t straightforward, and actually involves various subprocesses – including anticipation, motivation, pleasure and learning about reward.

Treatment options

    • For instance, research shows that talking therapies which focus on reward processing could help reduce anhedonia.
    • This is because augmented depression therapy specifically targets anhedonia by having patients focus on both their negative and positive experiences.
    • Read more:
      The science behind why hobbies can improve our mental health

      If you think you have anhedonia – or other symptoms of depression – it’s important not to ignore your feelings so you can get the help and treatment you deserve.

Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder

Retrieved on: 
Tuesday, July 18, 2023
Mental Health, Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Depression, KOR, Week, Baylor University, NDA, Hamilton Rating Scale for Depression, Dopamine, Science and technology in Asia, Prunus, Anhedonia, Acquisition, DSM-IV codes, MDD, Patient, Baylor College of Medicine, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Psychiatry, Food, Safety, Pharmaceutical industry, Medical device, MADRS

Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the planned initiation of the KOASTAL Program, a Phase 3 pivotal clinical program designed to evaluate the efficacy and safety of navacaprant (NMRA-140) monotherapy for the treatment of major depressive disorder (MDD).

Key Points: 
  • Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the planned initiation of the KOASTAL Program, a Phase 3 pivotal clinical program designed to evaluate the efficacy and safety of navacaprant (NMRA-140) monotherapy for the treatment of major depressive disorder (MDD).
  • The planned initiation follows the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and a robust Phase 2 study with navacaprant.
  • The KOASTAL Program will also include an open-label extension study, KOASTAL-LT, designed to evaluate the long-term safety of navacaprant.
  • The Phase 2 clinical trial was initiated by BlackThorn Therapeutics prior to its acquisition by Neumora and was a double-blind, placebo-controlled, randomized, multicenter trial of once-daily navacaprant monotherapy compared to placebo.